Replies to post #3277 on BioCurex, Inc.(fka BOCX)

[bocxman]

Headache: IMO you're misreading it...first of all Abbott was willing to license serum RECAF in it's old form, so why wouldn't others? That's like saying Harvard will accept you but not the local City College.

BOCX was very clear that the decision to move to a new assay type as it related to potential licensees was based on having a position of LEVERAGE in negotiations. This tells me that they learned from the ABT experience that the big boys want a colorimetric assay so give them one.

[erthang]

Headache - I think you are coming from a very pessimistic point of view. The fact that pharmas are interested enough to sit down with Biocurex to discuss a licensing agreement is good news. You must not be familiar with business negotiation. Sometimes, the end result is that both sides can't agree on terms. You are not privy to any information about the terms, or the sticking points in those discussions. Therefore your speculations don't have any merit.

They have developed this new improved format to the point where they feel comfortable reporting on it. So they must be using it currently! That is not to say that they are not still improving on it.

I say you are very pessimistic because it doesn't seem logical to me, for you to interpret an "improvement" in the format as a negative! Not to mention the "new focus" on demonstrating that recaf can detect early forms of cancers. This is great news! If the technology demonstrates it can detect most forms of cancers early, it should capture headlines and television coverage! Sounds like you are a hungry man, who can't appreciative of appetizer because it's not the meal!